Analyst: Lucentis Set To Grab 'Majority' Of Market For AMD
Lucentis is on the march. Again.
Last week, Genentech Inc. released the detailed data from the Phase III MARINA study of Lucentis (ranibizumab) in wet age-related macular degeneration, confirming interim data disclosed in May - but the news got even better.
To continue reading subscribe now to BioWorld Insight
Learn More about BioWorld Insight
Already a subscriber? Sign In or Buy now to activate your subscription
Our address has changed:
BioWorld | 115 Perimeter Center Place
Suite: 1100 | Atlanta, Georgia 30346, USA
Suite: 1100 | Atlanta, Georgia 30346, USA
For Sales Inquiries:
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
Fax: 1-770-810-3145
BioWorld.salessupport@thomsonreuters.com
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
Fax: 1-770-810-3145
BioWorld.salessupport@thomsonreuters.com
Part of Thomson Reuters
Note: our contact information has changed
Customer Service:
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
bioworld.support@thomsonreuters.com
Hours: Monday - Friday, 8:00am - 6:00 pm EST
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
bioworld.support@thomsonreuters.com
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2013 Thomson Reuters. Reproduction, reposting content is strictly prohibited.
Free Ezine
Sign up for Perspectives FREE e-mail newsletter